Ulipristal: a progesterone receptor antagonist as an emergency contraceptive

References

• Glasier A. Emergency postcoital contraception. N. Engl. J. Med.337(15), 1058–1064 (1997).
   PubMed Web of Science ®Google Scholar
• Cheng L, Gülmezoglu AM, Piaggio G, Ezcurra E, Van Look PFA. Interventions for emergency contraception. Cochrane Database Syst. Rev.16(2), CD001324 (2008).
   Google Scholar
• Farley TMM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet339 (8796), 785–788 (1992).
   PubMed Web of Science ®Google Scholar
• Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzmán-Rodríguez R. Use of copper intrauterine devices and the risk of tubal fertilization among nulligravid women. N. Engl. J. Med.345(8), 561–567 (2001).
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum. Reprod. Update11(3), 293–307 (2005).
   PubMed Web of Science ®Google Scholar
• Spitz IM, Croxatto HB, Robbins A. Antiprogestins: mechanism of action and contraceptive potential. Annu. Rev. Pharmacol. Toxicol.36, 47–81 (1996).
   PubMed Web of Science ®Google Scholar
• Creinin MD, Schiaff W, Archer DF et al. Progesterone receptor modulator for emergency contraception: a randomized controlled trial. Obstet. Gynecol.108(5), 1089–1097 (2008).
   Web of Science ®Google Scholar
• Trussell J, Stewart F, Guest F, Hatcher RA. Emergency contraceptive pills: a simple proposal to reduce unintended pregnancies. Fam. Plann. Perspect.24 (6), 269–273 (1992).
   PubMedGoogle Scholar
• WHO. Selected Practice Recommendations for Contraceptive Use (2nd edition). WHO, Geneva, Switzerland (2004).
   Google Scholar
• WHO. WHO Model Formulary 2004. Mehta DK, Ryan RSM, Hogerzeil HV (Eds). Bath Press, Bath, UK, 528 (2004).
   Google Scholar
• Trussell J, Koening J, Ellerston C, Stewart F. Preventing unintended pregnancy: the cost–effectiveness of three methods of emergency contraception. Am. J. Public Health87(6), 932–937 (1997).
   PubMed Web of Science ®Google Scholar
• Ngai SW, Fan S, Li S et al. A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emrgency contraception. Hum. Reprod.20(1), 307–311 (2005).
   PubMed Web of Science ®Google Scholar
• Ashok PW, Stalder C, Wagaarachchi PT, Flett GM, Melvin L, Templeton A. A randomized study comparing a low dose of mipepristone and the Yuzpe regimen for emergency contraception. BJOG109(5), 553–560 (2002).
   PubMed Web of Science ®Google Scholar
• Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet352(9126), 428–433 (1998).
   PubMed Web of Science ®Google Scholar
• Von Hertzen H, Piaggio G, Ding J et al. A low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet360(9348), 1803–1810 (2002).
   PubMed Web of Science ®Google Scholar
• Lakha F, Ho PC, Van der Spuy ZM et al. A novel estrogeno-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonogestrel). Hum. Reprod.22(9), 2428–2436 (2007).
   PubMed Web of Science ®Google Scholar
• Orihuela PA. Ulipristal, a progesterone receptor antagonist as a contraceptive and for the treatment of uterine fibroids. Curr. Opin. Investig. Drugs8(10), 859–866 (2007).
   PubMed Web of Science ®Google Scholar
• Wagner BL, Polio G, Giangrande P et al. The novel progesterone receptor antagonist RTI 3021–3012 and RTI 3021–3022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins. Endocrinology140(3), 1449–1458 (1999).
   PubMed Web of Science ®Google Scholar
• Cook CE, Raje P, Lee DY, Kepler JA. Effect of a 17α-(3-hydroxypropyl)-17β-acetyl substitutents pattern on the glucocorticoid and progestin receptor binding of 11β-arylestra-4,9-dien-3-ones. Org. Lett.3(7), 1013–1016 (2001).
   PubMed Web of Science ®Google Scholar
• Koper JW, Molijn GJ, van Uffelen CJC, Stigter E, Lamberts SW. Antiprogestins and iatrogenic glucocorticoid resistance. Life Sci.60(9), 617–624 (1997).
   PubMed Web of Science ®Google Scholar
• Gainer EE, Ulmann A. Pharmacologic properties of CDB(VA)-2914. Steroids68(10–13), 1005–1011 (2003).
   PubMed Web of Science ®Google Scholar
• Rao PN, Wang Z, Cessac JW, Rosenberg RS, Jenkins DJ, Diamandis EP. New 11β-aryl-substituted steroids exhibit both progestional and antiprogestional activity. Steroids63(10), 523–530 (1998).
   PubMed Web of Science ®Google Scholar
• Larner JM, Reel JR, Blye RP. Circulating concentrations of the antiprogestin CDB-2914 and mifepristone in the female rhesus monkey following various routes of administration. Hum. Reprod.15(5), 1100–1106 (2000).
   PubMed Web of Science ®Google Scholar
• Blithe DL, Nieman LK, Blye RP, Stratton P, Passaro M. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids68(10–13), 1013–1017 (2003).
   PubMed Web of Science ®Google Scholar
• Passaro MD, Piquion J, Mullen N et al. Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women. Hum. Reprod.18(9), 1820–1827 (2003).
   PubMed Web of Science ®Google Scholar
• Stratton P, Hartog B, Hajizadeh N et al. A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women. Hum. Reprod.15(5), 1092–1099 (2000).
   PubMed Web of Science ®Google Scholar
• Christian R, Stratton P, Merino MJ et al. The selective progesterone receptor modulator CDB-2914 has estrogenic and anti-estrogenic effects in menopausal women. Presented at: The Endocrine Society’s 84th Annual Meeting. San Francisco, CA, USA, 19–22 June 2002 (abstract 3–38).
   Google Scholar
• Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P; VA2914 Study Group. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic–pituitary–ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab.92(9), 3582–3589 (2007).
   PubMed Web of Science ®Google Scholar
• Spitz IM. Progesterone receptor antagonists. In: Nuclear Receptors as Drug Targets. Ottow E, Weinmann H (Eds). Wiley-VCH Verlag GmbH & Co, Germany, 223–248 (2008).
   Google Scholar
• Levens ED, Potlog-Nahari C, Armstrong AY et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet. Gynecol.111(5), 1129–1136 (2008).
   PubMed Web of Science ®Google Scholar
• Massai MR, Forcelledo ML, Brache V et al. Does meloxicam increase the incidence of anovulation induced by single administration of levonorgestrel in emergency contraception? A pilot study. Hum. Reprod.22(2), 434–439 (2007).
   PubMed Web of Science ®Google Scholar